| Literature DB >> 21687499 |
Francesco Miceli1, Maria Virginia Soldovieri, Fabio Arturo Iannotti, Vincenzo Barrese, Paolo Ambrosino, Maria Martire, Maria Roberta Cilio, Maurizio Taglialatela.
Abstract
Understanding the molecular mechanisms underlying voltage-dependent gating in voltage-gated ion channels (VGICs) has been a major effort over the last decades. In recent years, changes in the gating process have emerged as common denominators for several genetically determined channelopathies affecting heart rhythm (arrhythmias), neuronal excitability (epilepsy, pain), or skeletal muscle contraction (periodic paralysis). Moreover, gating changes appear as the main molecular mechanism by which several natural toxins from a variety of species affect ion channel function. In this work, we describe the pathophysiological and pharmacological relevance of the gating process in voltage-gated K(+) channels encoded by the K(v)7 gene family. After reviewing the current knowledge on the molecular mechanisms and on the structural models of voltage-dependent gating in VGICs, we describe the physiological relevance of these channels, with particular emphasis on those formed by K(v)7.2-K(v)7.5 subunits having a well-established role in controlling neuronal excitability in humans. In fact, genetically determined alterations in K(v)7.2 and K(v)7.3 genes are responsible for benign familial neonatal convulsions, a rare seizure disorder affecting newborns, and the pharmacological activation of K(v)7.2/3 channels can exert antiepileptic activity in humans. Both mutation-triggered channel dysfunction and drug-induced channel activation can occur by impeding or facilitating, respectively, channel sensitivity to membrane voltage and can affect overlapping molecular sites within the voltage-sensing domain of these channels. Thus, understanding the molecular steps involved in voltage-sensing in K(v)7 channels will allow to better define the pathogenesis of rare human epilepsy, and to design innovative pharmacological strategies for the treatment of epilepsies and, possibly, other human diseases characterized by neuronal hyperexcitability.Entities:
Keywords: Kv7 channels; anticonvulsant drugs; epilepsy; gating; neuronal excitability; potassium channels; retigabine; voltage-sensing
Year: 2011 PMID: 21687499 PMCID: PMC3108560 DOI: 10.3389/fphar.2011.00002
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1K.
Benign familial neonatal seizures-causing mutations localized in K.
| Amino acid change | Localization | Additional clinical data (beside BFNS) | Functional effects | Reference |
|---|---|---|---|---|
| p.E119G | S1–S2 linker | Generalized clonic seizures | Slight rightward shift in current voltage dependence in the sub-threshold region; Slight decrease in current activation kinetics | Wuttke et al. ( |
| p.S122L | Febrile seizures in later life; seizures until 7 years | Rightward shift in current voltage dependence in the sub-threshold region; decrease in current activation kinetics | Hunter et al. ( | |
| p.A196V | S4 | – | Rightward shift in current voltage dependence; decrease in current activation kinetics; novel pre-pulse-dependence of current activation kinetics | Soldovieri et al. ( |
| p.A196V;L197P | – | Rightward shift in current voltage-dependence; decrease in current activation kinetics | Soldovieri et al. ( | |
| p.R207W | Myokymia | Marked rightward shift in current voltage dependence; dramatic decrease in current activation kinetics | Dedek et al. ( | |
| p.R207Q | Myokymia (no BFNS) | Rightward shift in current voltage dependence; decrease in current activation kinetics | Wuttke et al. ( | |
| p.M208V | Generalized seizures between 4 and 7 years | Small decrease in maximal current; increased rate of channel deactivation | Singh et al. ( | |
| p.D212G | Rightward shift in current voltage dependence; increased rate of channel deactivation | Miceli et al. ( | ||
| p.R213W | – | – | Sadewa et al. ( | |
| p.R214W | – | Slight rightward shift in current voltage dependence; no effect on maximal current amplitude | Miraglia del Giudice et al. ( | |
| p.H228Q | S4–S5 linker | – | – | Singh et al. ( |
Figure 2Sequence alignment of the relevant VSD regions of VGKCs (.
Figure 3An homology model for K. Both panels show side views of a single Kv7.2 subunit at lower (left) and higher (right) magnification. (A) Shows the activated configuration of the subunit and the corresponding VSD, whereas (B) shows the resting state. Amino acids involved in intra-subunit ion pairs in either resting and activated VSD configurations are shown. The homology model of the activated VSD of the Kv7.2 channel was generated as previously described (Miceli et al., 2008b); the resting state was derived from the corresponding model of the Kv1.2 channel described by Pathak et al. (2007).
Figure 4An homology model for drug binding to K. Top view of the overall structure of the channel formed by four identical Kv7.2 subunits (A), and enlarged view of a single Kv7.2 subunit (B) captured in the activated configuration. The residues involved in binding of retigabine (indicated in orange), zinc pyrithione (indicated in yellow), and NH29 (indicated in green) highlighted. The L275 residue in the pore, common to both retigabine and zinc pyrithione binding, is indicated in violet. The S1 region has been removed for clarity. The homology model of the Kv7.2 channel was generated as previously described (Miceli et al., 2008b).
Residues presumably involved in binding different I.
| Drugs | Binding site | Reference |
|---|---|---|
| R198 (S4), L200 (S4), R207 (S4), and R214 (S4)Retigabine | W236 (S5), L243 (S5), L275 (pore), L299 (S6 of the neighboring subunit), and G301 (S6) | Wuttke et al. ( |
| Zinc pyrithione | L249 (S5), L275 (pore), and A306 (S6) | Xiong et al. ( |
| Diphenylamine carboxylate derivate NH29 | K120 (loop S1–S2), Y127 (S2), E130 (S2), L197 (S4), R198 (S4), L200 (S4), R207 (S4), and R214 (S4) | Peretz et al. ( |
| ICA-27243 | S1-S4 transmembrane domain | Padilla et al. ( |
| Acrylamide derivate (S)-1 | W242 (S5; according to Kv7.4 numbering) | Bentzen et al. ( |
| BMS-204354 | W242 (S5; according to Kv7.4 numbering) | Bentzen et al. ( |
| NEM ( | C242 (S5); C519 (C-terminal; according to Kv7.4 numbering) | Li et al. ( |
| H2O2 | C150 to C153 | Gamper et al. ( |